审阅要点
研究材料、活性成分和获批药品是不同类别。研究用途标签不能替代采购、进口、操作或使用所适用的要求。
准备咨询
请提供产品或序列、配置、数量、目的地和所需文档，以便团队评估范围并确认可提供的信息。
来源与核实范围
Anvisa orienta sobre importação de insumos para canetas de GLP-1 ↗
ANVISA
来源详情（原文语言）
- 范围
- Historical guidance on GLP-1 active ingredients
- 文件位置
- Identification and commercial import sections
- 局限
- Must be read with later updates; does not establish eligibility of RUO catalog products.
- 陈述核实日期
- 2026-09-09
Novas medidas sobre importação e manipulação de GLP-1 ↗
ANVISA
来源详情（原文语言）
- 范围
- Announcement of inspection and review measures
- 文件位置
- Inspection and proposed regulatory review measures
- 局限
- Announcement is not a blanket authorization or a complete consolidated legal rule.
- 陈述核实日期
- 2026-09-09
Importing Biological Materials into the United States ↗
U.S. Customs and Border Protection
来源详情（原文语言）
- 范围
- US import requirements depend on material and applicable agencies
- 文件位置
- Agency requirements and scope
- 局限
- Research use does not automatically remove applicable requirements; no universal catalog admission claim.
- 陈述核实日期
- 2026-09-09
FDA approves new medication for chronic weight management ↗
FDA
来源详情（原文语言）
- 范围
- US approval of Zepbound (tirzepatide) for the stated adult indication
- 文件位置
- Zepbound approval announcement
- 局限
- Approval applies to that medicinal product and jurisdiction, not research vials.
- 陈述核实日期
- 2026-09-09